Medibiofarma announces the nomination of a second Development Candidate
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
To make disease-modifying first-in-class immuno-oncology treatments available to patients suffering from devastating conditions such as cancer
Medibiofarma focused internal resources on areas where lies the experience of the management team:
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as in vivo pharmacology and toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Compound MBF-118, a novel PPAR-γ receptor modulator for the treatment of cancer. The compound will start IND enabling studies the second quarter 2018.